Stay updated with breaking news from Gene Expression Modulation System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only...
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV -
- Epic’s non-cutting technology to modulate the epigenome advances with the addition of new hypercompact Cas effectors and potent gene activators -SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins,...
Here are six biotech spinouts across the globe that have received funding over the past year, that you should know about.